New insights into acquired temozolomide resistance in glioblastoma? by Happold, Caroline & Weller, Michael
MSA. Neuropathol Appl Neurobiol 2007;
33: 615–20.
Wenning GK, Colosimo C, Geser F, Poewe
W. Multiple system atrophy. Lancet
Neurol 2004; 3: 93–103.
Wenning GK, Geser F, Krismer F, Seppi K,
Duerr S, Boesch S, et al. European
Multiple System Atrophy Study Group.
The natural history of multiple system
atrophy: a prospective European co-
hort study. Lancet Neurol 2013; 12:
264–74.
New insights into acquired temozolomide
resistance in glioblastoma?
This scientiﬁc commentary refers to
‘c-Myc–miR-29c–REV3L signalling
pathway drives the acquisition of
temozolomide resistance in glioblast-
oma’ by Luo et al. (doi:10.1093/
brain/awv287)
The emergence of tumour cell resist-
ance to chemotherapy represents a
major challenge for the development
of durable therapeutic strategies
across most solid cancers including
glioblastoma, the most malignant pri-
mary brain tumour in adults. The
standard of care for glioblastoma is
maximum surgery as safely feasible
followed by radiotherapy, with con-
comitant and maintenance chemo-
therapy with the alkylating agent
temozolomide (TMZ/RT!TMZ).
This results in a median overall sur-
vival in the range of 12 months on a
population level (Weller et al., 2014).
Radiotherapy alone doubled median
survival in early studies, but the
best radiological response is com-
monly stable disease, progression is
inevitable, and the efﬁcacy of radio-
therapy may be partly related to
anti-angiogenic rather than intrinsic
tumour cell cytotoxic effects.
Mechanisms underlying resistance to
radiotherapy remain poorly under-
stood, but extensive hypoxia may be
an important factor.
TMZ was approved for the treat-
ment of newly diagnosed glioblast-
oma because of a moderate
prolongation of median survival
(Stupp et al., 2005). Subgroup ana-
lyses revealed that the beneﬁt from
TMZ was largely restricted to pa-
tients with glioblastomas that exhibit
a particular epigenetic alteration,
promoter methylation of the O6-
methylguanine DNA methyltransfer-
ase (MGMT) gene (Hegi et al.,
2005). However, even these patients
eventually all progress and succumb
to their disease, in the absence of
changes in MGMT promoter methy-
lation (Felsberg et al., 2011), indicat-
ing that novel pathways must be
activated to escape from alkylating
agent chemotherapy.
Considerable efforts have been
made to understand and overcome
glioma cell resistance to chemother-
apy, focusing on several proteins and
pathways involved in cell survival and
resistance, including the mismatch
repair (MMR) pathway. In this issue
of Brain, Luo and co-workers report
that a c-Myc driven downregulation
of microRNA (miR)-29c promotes a
TMZ-resistant phenotype of glioma
cells that is mediated by increased
REV3L expression and consequent
enhanced DNA repair capacity (Luo
et al., 2015).
MicroRNAs have been studied ex-
tensively over the last decade for their
role in diverse biological processes,
especially in cell proliferation and
cell death. These small non-coding
RNA molecules can affect post-
transcriptional control of gene expres-
sion and may thereby help to regulate
several aspects of tumorigenesis,
including invasiveness, DNA repair,
and acquired resistance to genotoxic
cancer therapy. MicroRNAs can func-
tion as either tumour suppressors or
promoters, in a context-dependent
manner. While downregulation of
miR-29c has been associated with
tumorigenesis and invasiveness in a
variety of cancers, including gliomas
(Fan et al., 2013; Wang et al.,
2013), no link to TMZ resistance
has been established so far.
Here, Luo and co-workers used
quantitative PCR and in situ hybrid-
ization to conﬁrm a downregulation
of miR-29c—which was selected
from an array-based analysis of
matched primary and recurrent
human gliomas considered TMZ-
resistant—in recurrent tumour sam-
ples and cell lines selected for TMZ
resistance (U251/TMZR, U87/
TMZR). Restoration of miR-29c ex-
pression restored TMZ sensitivity. By
contrast, inhibition of miR-29c in
A172 cells, which express high levels
of miR-29c comparable to those of
normal human astrocytes, conferred
TMZ resistance. These effects were
reproduced in an in vivo model of
non-obese diabetic (NOD)-severe
combined immunodeﬁciency (SCID)
mice injected subcutaneously with re-
sistant U251/TMZR cells. Prolonged
survival was noted in animals treated
with intraperitoneal TMZ at 20mg/
kg and simultaneous intratumoural
injection of miR-29c (1 nmol), applied
as cholesterol-conjugated 2’-O-
methylmodiﬁed miR-29c for better
pharmacokinetic properties.
To assess potential target genes that
could be mediating the effect of miR-
29c, Luo et al. used a somewhat arti-
ﬁcial or at least unconventional ap-
proach: they generated a list of
candidate genes that were (i) deregu-
lated in TMZ-resistant cell lines that
had been engineered to overexpress
miR-29c; and (ii) also predicted tar-
gets of miR-29c according to public
databases. They identiﬁed REV3L, a
DNA repair polymerase previously
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linked to TMZ resistance (Roos et al.,
2009), as less strongly expressed in
the resistant cells with ectopic miR-
29c expression; accordingly, inhib-
ition of miR-29c by commercially
available antisense miR-29c molecules
in A172 cells led to an increase in
REV3L levels. A luciferase reporter
assay conﬁrmed direct targeting of
the 3’UTR on the REV3L mRNA
by miR-29c.
In an intracranial mouse model
consisting of animals injected with
primary GBM-2 or GBM-4 glioblast-
oma cells, prior transfection of the
tumour cells with miR-29c-mimics
reduced REV3L levels determined
by immunohistochemistry, reduced
tumour burden and increased survival
when the mice were treated with
TMZ. Moreover, when short hairpin
(sh)REV3L was used to block REV3L
expression in resistant GBM-2 and
GBM-4 cells expressing anti-miR-
29c, a sensitizing effect to TMZ was
noted. This was shown in vitro by
decreased colony formation ability
and increased apoptosis, and in vivo
by reduced tumour volume. The most
likely mechanism by which REV3L
overexpression produces TMZ resist-
ance is through sustained DNA
repair, since U87 scramble-transduced
cells showed more rapid DNA re-
pair than U87 cells with miR-29c
overexpression or REV3L gene silen-
cing. These cells exhibited increased
levels of -H2AX foci, a reaction
to DNA double-strand breaks, and
Figure 1 Proposed mechanism of TMZ resistance in glioblastoma. Upregulation of the miR-29c suppressor c-Myc leads to increased
expression of REV3L, resulting in enhanced DNA repair and chemoresistance. Potential approaches to counteract this pathway are indicated on
the right.
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chromosomal breakage in response to
TMZ.
Lastly, the authors identify c-Myc,
a transcription factor involved in cell
cycle progression and apoptosis that
is often constitutively expressed in
cancer cells, as an important positive
upstream regulator of the newly
described miR-29c/REV3L axis,
acting as an miR-29c suppressor and
thus indirect REV3L inducer. Taken
together, therefore, Luo et al. propose
a signalling axis whereby TMZ resist-
ance mediated by improved DNA
repair is achieved through c-Myc-
induced suppression of miR-29c with
consecutive REV3L induction (Fig.
1). The clinical relevance of these
ﬁndings was underlined by a Kaplan-
Meier survival analysis of 138 glio-
blastoma patients treated according to
standard of care (TMZ/RT!TMZ).
Patients with higher miR-29c levels re-
portedly had better survival rates. Of
note, the tissue specimens with high
miR-29c expression had lower levels
of c-Myc and REV3L, as predicted
from the in vitro ﬁndings.
This study has some limitations,
including the use of a subcutaneous
rather than intracranial tumour
model in some experiments, the arti-
ﬁcial approach to identifying REV3L
as a target of miR-29c, and the lack
of cross-resistance to explore whether
this pathway is speciﬁc to TMZ or is
relevant for other alkylators such as
CCNU, too, or for drugs with
different modes of action, or even
for radiotherapy.
Importantly, the regulation of TMZ
resistance reported here was observed
in primary glioblastoma cells with or
without MGMT expression.
Accordingly, no regulation of
MGMT levels was observed when
cells were exposed to miR-29c
mimics or inhibitors. Moreover, no
role was identiﬁed for the MMR
pathway in this resistance either.
Thus, the interaction of miR-29c
and REV3L could represent an inter-
esting therapeutic target for all glio-
blastomas, with or without MGMT
promoter methylation, provided that
this network can be selectively tar-
geted in neoplastic cells.
Future studies should explore which
factors regulate c-Myc expression up-
stream of this resistance pathway.
Knowledge of this upstream mechan-
ism and factors modulating the down-
stream cascade would allow for
potential therapeutic interventions,
focusing for example on clinically ap-
plicable microRNA mimics or REV3L
inhibitors.
Caroline Happold and Michael Weller
Department of Neurology, University
Hospital and University of Zurich, Zurich,
Switzerland
Correspondence to: Michael Weller
E-mail: michael.weller@usz.ch
doi:10.1093/brain/awv301
References
Fan YC, Mei PJ, Chen C, Miao FA, Zhang
H, Li ZL. MiR-29c inhibits glioma cell
proliferation, migration, invasion and
angiogenesis. J Neurooncol 2013; 115:
179–88.
Felsberg J, Thon N, Eigenbrod S, Hentschel
B, Sabel MC, Westphal M, et al. Promoter
methylation and expression of MGMT
and the DNA mismatch repair genes
MLH1, MSH2, MSH6 and PMS2 in
paired primary and recurrent glioblast-
omas. Int J Cancer 2011; 129: 659–70.
Hegi ME, Diserens AC, Gorlia T, Hamou
MF, de Tribolet N, Weller M, et al.
MGMT gene silencing and beneﬁt from
temozolomide in glioblastoma. N Engl J
Med 2005; 352: 997–1003.
Luo H, Chen Z, Wang S, Zhang R, Qiu W,
Zhao L, et al. c-Myc-miR-29c-REV3L sig-
naling pathway drives the acquisition of
temozolomide resistance in glioblastoma.
Brain 2015; 138: 3654–3672.
Roos WP, Tsaalbi-Shtylik A, Tsaryk R,
Guvercin F, de Wind N, Kaina B. The
translesion polymerase Rev3L in the toler-
ance of alkylating anticancer drugs. Mol
Pharmacol 2009; 76: 927–34.
Stupp R, Mason WP, van den Bent MJ,
Weller M, Fisher B, Taphoorn MJ, et al.
Radiotherapy plus concomitant and adju-
vant temozolomide for glioblastoma. N
Engl J Med 2005; 352: 987–96.
Wang Y, Li Y, Sun J, Wang Q, Sun C, Yan
Y, et al. Tumor-suppressive effects of miR-
29c on gliomas. Neuroreport 2013; 24:
637–45.
Weller M, van den Bent M, Hopkins K,
Tonn JC, Stupp R, Falini A, et al. EANO
guideline for the diagnosis and treatment
of anaplastic gliomas and glioblastoma.
Lancet Oncol 2014; 15: e395–403.
Lipidated APOE has effects on cognitive
function that are independent of amyloid-b
pathology
This scientiﬁc commentary refers to
‘Opposing effects of Apoe/Apoa1
double deletion on amyloid-b path-
ology and cognitive performance in
APP mice’, by Fitz et al.
(doi:10.1093/brain/awv293).
Since the discovery of the apolipopro-
tein E "4 allele (APOE4) as the stron-
gest genetic risk factor for Alzheimer’s
disease (reviewed by Verghese et al.,
2011), there has been a dramatic in-
crease in research on the intersection
of lipid biology and Alzheimer path-
ology. APOE is the major cholesterol
and lipid carrier in the brain,
while apolipoprotein A1 (APOA1) is
the major lipid carrier in the per-
iphery. Efﬂux of cholesterol and
3470 | BRAIN 2015: 138; 3466–3475 Scientific Commentaries
